Are hemostasis and thrombosis two sides of the same coin?

Factor XII (FXII), a clotting enzyme that can initiate coagulation in vitro, has long been considered dispensable for normal blood clotting in vivo because hereditary deficiencies in FXII are not associated with spontaneous or excessive bleeding. However, new studies show that mice lacking FXII are...

Descripción completa

Detalles Bibliográficos
Autor principal: Colman, Robert W.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2006
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118234/
https://www.ncbi.nlm.nih.gov/pubmed/16533890
http://dx.doi.org/10.1084/jem.20060217
_version_ 1782140979450478592
author Colman, Robert W.
author_facet Colman, Robert W.
author_sort Colman, Robert W.
collection PubMed
description Factor XII (FXII), a clotting enzyme that can initiate coagulation in vitro, has long been considered dispensable for normal blood clotting in vivo because hereditary deficiencies in FXII are not associated with spontaneous or excessive bleeding. However, new studies show that mice lacking FXII are protected against arterial thrombosis (obstructive clot formation) and stroke. Thus, FXII could be a unique drug target that could be blocked to prevent thrombosis without the side effect of increased bleeding.
format Text
id pubmed-2118234
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21182342007-12-13 Are hemostasis and thrombosis two sides of the same coin? Colman, Robert W. J Exp Med Commentaries Factor XII (FXII), a clotting enzyme that can initiate coagulation in vitro, has long been considered dispensable for normal blood clotting in vivo because hereditary deficiencies in FXII are not associated with spontaneous or excessive bleeding. However, new studies show that mice lacking FXII are protected against arterial thrombosis (obstructive clot formation) and stroke. Thus, FXII could be a unique drug target that could be blocked to prevent thrombosis without the side effect of increased bleeding. The Rockefeller University Press 2006-03-20 /pmc/articles/PMC2118234/ /pubmed/16533890 http://dx.doi.org/10.1084/jem.20060217 Text en Copyright © 2006, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Commentaries
Colman, Robert W.
Are hemostasis and thrombosis two sides of the same coin?
title Are hemostasis and thrombosis two sides of the same coin?
title_full Are hemostasis and thrombosis two sides of the same coin?
title_fullStr Are hemostasis and thrombosis two sides of the same coin?
title_full_unstemmed Are hemostasis and thrombosis two sides of the same coin?
title_short Are hemostasis and thrombosis two sides of the same coin?
title_sort are hemostasis and thrombosis two sides of the same coin?
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118234/
https://www.ncbi.nlm.nih.gov/pubmed/16533890
http://dx.doi.org/10.1084/jem.20060217
work_keys_str_mv AT colmanrobertw arehemostasisandthrombosistwosidesofthesamecoin

Ejemplares similares